These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 19539072)

  • 1. Impact of the definition utilized on the rate of contrast-induced nephropathy in percutaneous coronary intervention.
    Jabara R; Gadesam RR; Pendyala LK; Knopf WD; Chronos N; Chen JP; Viel K; King SB; Manoukian SV
    Am J Cardiol; 2009 Jun; 103(12):1657-62. PubMed ID: 19539072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of iso-osmolar versus low-osmolar contrast agents on contrast-induced nephropathy and tissue reperfusion in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the Contrast Media and Nephrotoxicity Following Primary Angioplasty for Acute Myocardial Infarction [CONTRAST-AMI] Trial).
    Bolognese L; Falsini G; Schwenke C; Grotti S; Limbruno U; Liistro F; Carrera A; Angioli P; Picchi A; Ducci K; Pierli C
    Am J Cardiol; 2012 Jan; 109(1):67-74. PubMed ID: 21943940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ratio of contrast volume to glomerular filtration rate predicts outcomes after percutaneous coronary intervention for ST-segment elevation acute myocardial infarction.
    Mager A; Vaknin Assa H; Lev EI; Bental T; Assali A; Kornowski R
    Catheter Cardiovasc Interv; 2011 Aug; 78(2):198-201. PubMed ID: 20949583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contrast-induced nephropathy in urgent coronary interventions.
    Valente S; Lazzeri C; Giglioli C; Margheri M; Comeglio M; Nicolaci L; Chechi T; Gensini GF
    J Cardiovasc Med (Hagerstown); 2006 Oct; 7(10):737-41. PubMed ID: 17001234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk scoring system for prediction of contrast-induced nephropathy in patients with pre-existing renal impairment undergoing percutaneous coronary intervention.
    Chong E; Shen L; Poh KK; Tan HC
    Singapore Med J; 2012 Mar; 53(3):164-9. PubMed ID: 22434288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention.
    Nie B; Cheng WJ; Li YF; Cao Z; Yang Q; Zhao YX; Guo YH; Zhou YJ
    Catheter Cardiovasc Interv; 2008 Dec; 72(7):958-65. PubMed ID: 19021282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Different Risk Scores for Predicting Contrast Induced Nephropathy and Outcomes After Primary Percutaneous Coronary Intervention in Patients With ST Elevation Myocardial Infarction.
    Liu YH; Liu Y; Zhou YL; He PC; Yu DQ; Li LW; Xie NJ; Guo W; Tan N; Chen JY
    Am J Cardiol; 2016 Jun; 117(12):1896-903. PubMed ID: 27161818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of contemporary definitions of contrast nephropathy in patients undergoing percutaneous coronary intervention and a proposal for a novel nephropathy grading system.
    Harjai KJ; Raizada A; Shenoy C; Sattur S; Orshaw P; Yaeger K; Boura J; Aboufares A; Sporn D; Stapleton D
    Am J Cardiol; 2008 Mar; 101(6):812-9. PubMed ID: 18328846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of contrast-induced nephrotoxicity of iodixanol and iopromide in patients with renal insufficiency undergoing coronary angiography.
    Shin DH; Choi DJ; Youn TJ; Yoon CH; Suh JW; Kim KI; Cho YS; Cho GY; Chae IH; Kim CH
    Am J Cardiol; 2011 Jul; 108(2):189-94. PubMed ID: 21545991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined impact of chronic kidney disease and contrast-induced nephropathy on long-term outcomes in patients with ST-segment elevation acute myocardial infarction who undergo primary percutaneous coronary intervention.
    Nakahashi H; Kosuge M; Sakamaki K; Kiyokuni M; Ebina T; Hibi K; Tsukahara K; Iwahashi N; Kuji S; Oba MS; Umemura S; Kimura K
    Heart Vessels; 2017 Jan; 32(1):22-29. PubMed ID: 27106917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B-type natriuretic peptide for prevention of contrast-induced nephropathy in patients with heart failure undergoing primary percutaneous coronary intervention.
    Zhang J; Fu X; Jia X; Fan X; Gu X; Li S; Wu W; Fan W; Su J; Hao G; Jiang Y; Xue L
    Acta Radiol; 2010 Jul; 51(6):641-8. PubMed ID: 20438292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Implications of Contrast-Induced Nephropathy in Patients Without Baseline Renal Dysfunction Undergoing Coronary Angiography.
    Chen SQ; Liu Y; Smyth B; Li HL; Sun GL; Chen ZJ; Zhou YL
    Heart Lung Circ; 2019 Jun; 28(6):866-873. PubMed ID: 29960836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of iodixanol and ioversol for the prevention of contrast-induced nephropathy in diabetic patients after coronary angiography or angioplasty.
    Hernández F; Mora L; García-Tejada J; Velázquez M; Gómez-Blázquez I; Bastante T; Albarrán A; Andreu J; Tascón J
    Rev Esp Cardiol; 2009 Dec; 62(12):1373-80. PubMed ID: 20038403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contrast-induced nephropathy after percutaneous coronary intervention in simple lesions: risk factors and incidence are affected by the definition utilized.
    Caruso M; Balasus F; Incalcaterra E; Ruggieri A; Evola S; Fattouch K; Bracale UM; Amodio E; Novo G; Andolina G; Novo S
    Intern Med; 2011; 50(9):983-9. PubMed ID: 21532220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention without acute left ventricular ejection fraction impairment.
    Pyxaras SA; Sinagra G; Mangiacapra F; Perkan A; Di Serafino L; Vitrella G; Rakar S; De Vroey F; Santangelo S; Salvi A; Toth G; Bartunek J; De Bruyne B; Wijns W; Barbato E
    Am J Cardiol; 2013 Mar; 111(5):684-8. PubMed ID: 23261003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of anemia on contrast-induced nephropathy (CIN) in patients undergoing percutaneous coronary interventions.
    Li WH; Li DY; Han F; Xu TD; Zhang YB; Zhu H
    Int Urol Nephrol; 2013 Aug; 45(4):1065-70. PubMed ID: 23225080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk score for contrast induced nephropathy following percutaneous coronary intervention.
    Ghani AA; Tohamy KY
    Saudi J Kidney Dis Transpl; 2009 Mar; 20(2):240-5. PubMed ID: 19237811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal tolerability of iopromide and iodixanol in 562 renally impaired patients undergoing cardiac catheterisation: the DIRECT study.
    Chen Y; Hu S; Liu Y; Zhao R; Wang L; Fu G; He Q; Su X; Zheng Y; Qi X; Liu H; Wang J; Gao W; Wang M; Liu S; Zheng X; He B; Yang P; Zhou S; Gao C; Qiu C
    EuroIntervention; 2012 Nov; 8(7):830-8. PubMed ID: 23045301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of anisodamine on prevention of contrast induced nephropathy in patients with acute coronary syndrome.
    Wang YB; Fu XH; Gu XS; Wang XC; Zhao YJ; Hao GZ; Jiang YF; Fan WZ; Wu WL; Li SQ; Xue L
    Chin Med J (Engl); 2012 Mar; 125(6):1063-7. PubMed ID: 22613532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of contrast-induced nephropathy in diabetics undergoing elective percutaneous coronary intervention: role of the ratio of contrast medium volume to estimated glomerular filtration rate.
    Wang XC; Fu XH; Wang YB; Jia XW; Wu WL; Gu XS; Zhang J; Su JL; Hao GZ; Jiang YF; Fan WZ; Li SQ
    Chin Med J (Engl); 2011 Mar; 124(6):892-6. PubMed ID: 21518598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.